Strongbridge Biopharma plc (NASDAQ:SBBP) will be hosting a conference call at 8:30 AM eastern time on 4th August 2020, to discuss its 2Q20 financial results with the investment community.
A live webcast with presentations will be available on the Internet by visiting the Company website www.strongbridgebio.com
Earnings Expectation
Strongbridge Biopharma plc is reporting second quarter earnings results on Tuesday 4th August 2020, before market open. The consensus estimates from Thomson Reuters are loss of $ 0.21 per share. For the full year, analysts predict revenues of $ 25.22 million, while looking forward to loss of $ 0.78 per share.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 22.00 million ~ $ 26.00 million
Click Here For More Historical Outlooks Of Strongbridge Biopharma plc
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The companys commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency. Its clinical-stage product candidates are Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trial that is used for the treatment of endogenous Cushings syndrome; and Veldoreotide, a somatostatin analog that completed Phase II clinical trial for the treatment of acromegaly.
